Brought to you by 
TaiGen brings in $38mm with Series B financing
19 Oct 2005
Executive Summary
TaiGen Biotechnology (focused on developing therapeutics for diseases most prevalent in Asians) has raised $38mm with the first close of its Series B venture round. China Steel led the financing and was joined by returning backers MPM Capital, Development Fund, YFY Group, China Development Industrial Bank, Shin Kong Life Insurance, and Cathay Life Insurance. The company plans to close a second tranche later this year.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TaiGen brings in $38mm with Series B financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice